Back to Search
Start Over
Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab.
- Source :
-
Annals of hematology [Ann Hematol] 2024 Apr; Vol. 103 (4), pp. 1397-1402. Date of Electronic Publication: 2024 Feb 17. - Publication Year :
- 2024
-
Abstract
- B/T mixed phenotype acute leukemia (MPAL), which represents only 2-3% of all MPAL cases, is classified as a high-risk leukemia subtype. Adults diagnosed with B/T MPAL have a notably low 3-year survival rate, estimated at 20-40%. The rarity and undercharacterization of B/T MPAL present substantial challenges in identifying an optimal treatment protocol. This report aims to shed light on this issue by presenting a case in which a patient with a complex karyotype was treated using a combination of venetoclax, azacitidine, and blinatumomab. This novel, chemo-free regimen resulted in the patient achieving both hematologic and molecular complete remission, with no severe organ or hematological toxicity observed. Notably, the patient continued to maintain molecular remission for 1 year following the transplantation. Based on these findings, the combination of venetoclax, azacitidine, and blinatumomab could be considered a potential therapeutic approach for B/T MPAL patients, meriting further investigation.<br /> (© 2024. The Author(s).)
Details
- Language :
- English
- ISSN :
- 1432-0584
- Volume :
- 103
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Annals of hematology
- Publication Type :
- Academic Journal
- Accession number :
- 38367057
- Full Text :
- https://doi.org/10.1007/s00277-024-05644-9